List of Excipients in Branded Drug BRIMONIDINE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	BRIMONIDINE TARTRATE	brimonidine tartrate	54868-6094	BORIC ACID
Physicians Total Care Inc	BRIMONIDINE TARTRATE	brimonidine tartrate	54868-6094	CALCIUM CHLORIDE
Physicians Total Care Inc	BRIMONIDINE TARTRATE	brimonidine tartrate	54868-6094	HYDROCHLORIC ACID
Physicians Total Care Inc	BRIMONIDINE TARTRATE	brimonidine tartrate	54868-6094	MAGNESIUM CHLORIDE
Physicians Total Care Inc	BRIMONIDINE TARTRATE	brimonidine tartrate	54868-6094	MANNITOL

Generic Drugs Containing BRIMONIDINE

Company	Ingredient	NDC	Excipient
Sandoz Inc	brimonidine tartrate	0781-7177	BORIC ACID
Sandoz Inc	brimonidine tartrate	0781-7177	CALCIUM CHLORIDE
Sandoz Inc	brimonidine tartrate	0781-7177	CARBOXYMETHYLCELLULOSE SODIUM
Sandoz Inc	brimonidine tartrate	0781-7177	HYDROCHLORIC ACID
Sandoz Inc	brimonidine tartrate	0781-7177	MAGNESIUM CHLORIDE

What are the Most Frequently-Used Excipients in BRIMONIDINE?

# Of NDCs	Excipient
4	BENZALKONIUM CHLORIDE
1	BORIC ACID
1	CALCIUM CHLORIDE
2	CARBOMER HOMOPOLYMER TYPE B
1	CARBOXYMETHYLCELLULOSE SODIUM

Last updated: September 3, 2026

Brimonidine is a mature alpha-2 adrenergic agonist with three commercially distinct formulation platforms: prescription ophthalmic solutions for glaucoma, prescription topical gel for persistent facial erythema associated with rosacea, and low-dose OTC ophthalmic solution for ocular redness. The strongest excipient opportunities are preservative-free multidose delivery, improved ocular comfort, longer residence time, differentiated dermal gels, and device-based dosing. The largest commercial risks are generic substitution in glaucoma, safety limits on systemic exposure, and the difficulty of establishing clinical equivalence for nontraditional delivery systems.

Brimonidine Excipient Strategy and Commercial Opportunities

What is brimonidine used for?

Brimonidine tartrate is an alpha-2 adrenergic receptor agonist that reduces aqueous humor production and increases uveoscleral outflow. Its approved and commercial uses include:

Product type	Representative product	Strength	Route	Primary use
Prescription ophthalmic solution	Alphagan P	0.1% and 0.15%	Topical ocular	Open-angle glaucoma and ocular hypertension
OTC ophthalmic solution	Lumify	0.025%	Topical ocular	Temporary relief of ocular redness
Prescription topical gel	Mirvaso	0.33%	Topical dermal	Persistent facial erythema associated with rosacea

The same active pharmaceutical ingredient supports different commercial propositions because dose, route, excipient system, packaging and regulatory pathway materially alter the product profile.

Brimonidine is highly potent at low concentrations, but systemic absorption can cause hypotension, bradycardia, fatigue and central nervous system effects. These risks are especially relevant in pediatric patients and patients receiving other cardiovascular or central nervous system medicines. Excipient selection must therefore prioritize low irritation, controlled release, uniform dosing and limited systemic exposure. (U.S. Food and Drug Administration [FDA], 2013, 2017, 2018)

What excipients are used in commercial brimonidine products?

Alphagan P ophthalmic solution

Alphagan P uses a low-dose preservative system based on Purite, an oxychloro complex designed to convert to natural tear components after administration. The formulation also uses buffering salts, tonicity agents and viscosity modification. The precise inactive-ingredient profile varies by strength and labeling presentation.

The formulation strategy addresses a central problem in chronic ophthalmic therapy: benzalkonium chloride can damage the ocular surface with repeated exposure. A Purite-based formulation allows the sponsor to position the product as more tolerable than conventional preserved glaucoma drops, although tolerability depends on the complete formulation and patient population rather than on preservative choice alone.

Commercially relevant excipient functions include:

• Oxidative preservation through Purite.
• pH control using borate buffers.
• Isotonicity adjustment using sodium chloride and related salts.
• Modest viscosity enhancement to reduce drainage through the nasolacrimal duct.
• Compatibility with multidose ophthalmic packaging.

The commercial opportunity is strongest in preservative-free or low-irritation products for patients with ocular surface disease, polypharmacy or chronic glaucoma treatment.

Lumify ophthalmic solution

Lumify contains brimonidine tartrate at 0.025%, substantially below the prescription glaucoma strengths. Its low concentration is central to the OTC positioning and is paired with a Purite-based preservative system and a buffered, isotonic vehicle. The product is designed for temporary vasoconstriction of ocular surface blood vessels rather than sustained intraocular pressure reduction. (FDA, 2018)

The Lumify platform illustrates how excipient strategy can support a consumer-health product:

1. The lower active concentration reduces the pharmacologic exposure required for redness relief.
2. The preservative system supports repeated consumer use.
3. The vehicle is compatible with a multidose dropper.
4. The formulation avoids the need for a high-viscosity gel that could impair visual comfort.

The main commercial risk is that the consumer proposition depends on a narrow balance between visible redness reduction, comfort, onset, duration and the absence of rebound redness or excessive vasoconstriction.

Mirvaso topical gel

Mirvaso is a 0.33% brimonidine tartrate topical gel for facial erythema caused by rosacea. Its formulation uses a carbomer-based gel system with humectants, preservatives, solvents and pH adjustment. Carbomer provides viscosity and supports residence on the facial skin. The formulation must spread easily, dry without unacceptable residue and deliver a controlled amount of brimonidine across facial skin.

The dermal excipient system creates different technical challenges from ophthalmic delivery:

• Skin penetration must be sufficient for local vasoconstriction but limited enough to reduce systemic exposure.
• The gel must minimize stinging, dryness and irritation on rosacea-affected skin.
• Dose uniformity must remain consistent when patients apply a thin layer to several facial zones.
• Packaging must limit contamination and support accurate daily application.
• The vehicle must remain stable under normal consumer storage conditions.

Mirvaso labeling warns about worsening erythema, flushing and systemic cardiovascular effects. These risks place practical limits on aggressive penetration enhancement. (FDA, 2017)

What excipient strategies offer the strongest commercial opportunity?

Preservative-free multidose ophthalmic delivery

Preservative-free multidose systems are the clearest high-value opportunity in prescription brimonidine. Conventional preservative-free unit-dose packaging increases manufacturing, packaging and distribution costs. A multidose container with a one-way valve, airless reservoir or antimicrobial closure can reduce waste and improve patient convenience.

A successful product would need to demonstrate:

• Microbiological integrity after repeated opening.
• Accurate drop delivery through the labeled in-use period.
• Compatibility between the container and brimonidine solution.
• Chemical stability of the active and preservative system.
• Acceptable extractables and leachables profile.
• Clinical tolerability comparable with or better than established products.

The IP position would likely center on the container-closure system, fill configuration, dosing mechanism and stability data rather than on brimonidine itself.

Lower-irritation glaucoma formulations

A formulation that removes benzalkonium chloride is commercially credible because glaucoma patients may use multiple topical medicines for years. Potential approaches include:

• Purite or other rapidly dissipating oxidative preservatives.
• Preservative-free unit-dose solutions.
• Low-preservative systems with improved packaging.
• Mild buffer systems with reduced ionic burden.
• Slightly increased viscosity to reduce drainage without blurring vision.
• pH and osmolality optimization to improve comfort.

The commercial ceiling is constrained by generic brimonidine solutions, which are generally price competitive. A new formulation would need a clear value proposition, such as documented ocular-surface benefits, reduced discontinuation or improved adherence.

Extended-residence ocular systems

Brimonidine could support sustained-delivery products using in situ gels, mucoadhesive polymers, nanosuspensions, lipid systems or depot inserts. These systems could reduce dosing frequency and nasolacrimal drainage.

The major technical risk is excessive exposure. Because brimonidine can produce systemic cardiovascular and central nervous system effects, prolonged ocular residence must not produce a high early peak or uncontrolled cumulative dose.

The most defensible development profile would be a modest extension of dosing interval rather than a highly concentrated depot. A product that delivers a stable low dose over 12 to 24 hours may be more commercially practical than a long-acting implant requiring an invasive procedure.

Dermal gels, creams and foams

The rosacea market offers room for differentiated brimonidine products. Potential product concepts include:

• A lower-residue gel for daytime use.
• A cream-gel with improved moisturization for dry or sensitive skin.
• A foam with rapid spreading over the central face.
• A polymer system that reduces runoff into the eyes.
• A metered pump that improves dose reproducibility.
• A formulation with lower preservative burden.
• A combination product pairing brimonidine with an approved rosacea active.

Combination products create a larger clinical and regulatory burden. They also create more substantial differentiation if the second active addresses papules, pustules, inflammation or barrier dysfunction rather than erythema alone.

Low-dose OTC ocular products

The OTC ocular redness segment has already established a commercial model for low-dose brimonidine. New entrants would face a difficult position if they offer only the same active and concentration in a conventional bottle. More credible differentiation would involve:

• Preservative-free packaging.
• Smaller travel-size formats.
• Single-use vials.
• Contact-lens-compatible positioning where supported by labeling.
• A faster or longer-lasting effect demonstrated in clinical studies.
• Packaging and branding designed for frequent consumer use.

Any change to concentration, indication, dosing or labeling could affect the regulatory route. A product that departs materially from the established OTC profile may require a new drug application rather than a simple private-label strategy.

What patents protect brimonidine formulations?

The active molecule and basic therapeutic use are mature. Commercial protection is more likely to arise from formulation, delivery, packaging, manufacturing and indication-specific claims.

Protection category	Typical claim focus	Commercial relevance
Active ingredient	Brimonidine or brimonidine tartrate	Limited value because of age and generic availability
Ophthalmic composition	Concentration, buffer, preservative, tonicity and viscosity	Relevant to differentiated glaucoma and redness products
Topical composition	Carbomer, solvent, humectant and pH system	Relevant to rosacea gel alternatives
Delivery device	Metered pump, airless container, multidose valve or dropper	Can create device-led differentiation
Method of use	Rosacea erythema, ocular redness or intraocular pressure reduction	May affect labeling and generic carve-outs
Manufacturing process	Mixing order, sterilization, impurity control and filling	Relevant where stability or scale-up is difficult
Combination therapy	Brimonidine with another active	Potentially valuable for rosacea or glaucoma

U.S. Orange Book protection must be assessed product by product because listed patents and regulatory exclusivities differ among Alphagan P, Mirvaso and other products. Patent expiration alone does not establish immediate generic entry. A challenger must also address active-ingredient sameness, inactive-ingredient differences, bioequivalence, labeling and any listed method-of-use claims. (FDA, 2025a)

When does brimonidine lose exclusivity?

Brimonidine has already lost core active-ingredient exclusivity in the United States. Generic brimonidine ophthalmic solutions are commercially established, creating substantial price pressure in glaucoma.

The commercial exclusivity analysis is product specific:

• Prescription glaucoma solutions face mature generic competition.
• OTC Lumify competes in a consumer market where branding, distribution and packaging are important because prescription-style ANDA substitution is not the only route to competition.
• Mirvaso faces formulation-specific generic risk because topical gel products require assessment of composition, rheology, application performance and local delivery.
• New excipient or device improvements may receive patent protection even when the active ingredient is unprotected.

A sponsor should not treat all brimonidine products as one patent estate. The commercial barriers for a generic ophthalmic solution are materially lower than for a dermal gel with a proprietary rheology profile or a preservative-free multidose device.

What is the FDA regulatory status of brimonidine products?

Brimonidine is regulated through different pathways depending on product type.

Prescription ophthalmic products

Glaucoma products are approved prescription drugs. Generic applicants generally use the abbreviated new drug application pathway and must establish pharmaceutical equivalence and bioequivalence under FDA requirements. Inactive ingredients may differ, but they cannot create an unacceptable safety or performance difference.

OTC ocular redness products

Low-dose brimonidine for ocular redness is marketed under an FDA-approved application. A competing product cannot assume that the prescription generic pathway applies to an OTC product with a different strength, indication and labeling profile.

Prescription topical rosacea products

Mirvaso is an NDA-approved topical product. A generic applicant must address topical product equivalence, including formulation, dosage form, physicochemical properties and performance. FDA guidance for topical dermatological products has increased the importance of comparative product characterization and in vitro release or permeation data where appropriate. (FDA, 2022)

Which companies are challenging brimonidine products?

Generic manufacturers have long competed in prescription brimonidine ophthalmic solutions. The principal competitive threat is therefore broad generic substitution rather than a single identifiable challenger.

For Mirvaso, competitive entry depends on whether an applicant can match the reference gel's quality attributes and satisfy FDA requirements for topical equivalence. Public litigation and Orange Book status should be reviewed by product and jurisdiction before a transaction, launch decision or patent-risk opinion. The existence of an ANDA filing, Paragraph IV certification or patent lawsuit can materially change the expected entry date.

A Paragraph IV challenge may target:

• Formulation claims.
• Concentration or particle-size claims.
• Gel rheology.
• Method-of-use claims for rosacea erythema.
• Stability or manufacturing claims.
• Device or packaging claims where listed.

A generic applicant may also pursue a Paragraph III certification, wait for patent expiration or use a section viii statement to omit a patented indication. The practical effect depends on the exact Orange Book listing and the scope of the reference product's labeling.

What patent litigation and settlements affect brimonidine?

Brimonidine litigation risk is concentrated in product-specific formulation and method-of-use patents rather than in the mature active ingredient. A litigation review should examine:

1. Orange Book-listed patents for the reference product.
2. ANDA filing dates and certification type.
3. District court complaints under the Hatch-Waxman framework.
4. Patent-term adjustments and pediatric extensions.
5. Settlement terms, including licensed entry dates and launch restrictions.
6. Whether a settlement includes supply, authorized-generic or royalty provisions.
7. Whether claims were invalidated, narrowed or disclaimed.

A settlement can create a commercial entry date that differs from the nominal patent expiration date. It can also preserve a branded product's market position through an authorized generic or a license to the challenger.

No single brimonidine litigation outcome determines the whole market. Alphagan P, Lumify and Mirvaso require separate reviews because they involve different dosage forms, sponsors, indications and regulatory pathways.

How strong is the brimonidine patent estate?

The estate is strongest where it protects a difficult-to-copy product configuration rather than a simple solution.

Product strategy	Patent strength	Generic risk	Main barrier
Standard brimonidine ophthalmic solution	Low to moderate	High	Limited formulation differentiation
Preservative-free unit-dose solution	Moderate	Moderate	Packaging, stability and patient-use data
Preservative-free multidose system	Moderate to strong	Moderate	Device and microbiological performance
Extended-release ocular formulation	Strong if clinically validated	Lower initially	Dose control, safety and bioequivalence
Mirvaso-like topical gel	Moderate	Moderate	Local equivalence and formulation matching
Novel foam or cream-gel	Moderate to strong	Lower initially	Clinical performance and manufacturing scale-up
Brimonidine combination product	Stronger if claims are specific	Moderate	Combination clinical development and labeling

Patent strength depends on claim breadth, written-description support, obviousness risk, enablement, freedom to operate and the availability of noninfringing alternative formulations. A narrow excipient claim can be commercially useful if it is difficult to design around, but it may be vulnerable if multiple conventional polymers, buffers or preservatives provide equivalent performance.

What manufacturing and IP barriers affect brimonidine?

Manufacturing is not inherently high barrier for a conventional brimonidine solution. The principal technical risks are:

• Sterile processing and aseptic filling.
• Control of impurities and degradation products.
• Container-closure compatibility.
• Preservative effectiveness.
• Drop-size consistency.
• Polymer hydration and gel uniformity.
• Batch-to-batch rheology for topical products.
• Extractables and leachables from pumps and multidose systems.
• Scale-up of low-dose formulations, where small concentration errors affect dose uniformity.

A novel device can improve commercial defensibility but may create a separate freedom-to-operate problem. Airless pumps, multidose ophthalmic valves, preservative-free closures and metered topical dispensers are often covered by third-party patents. A complete diligence program must analyze both drug patents and device patents.

How does brimonidine compare with competing redness and rosacea drugs?

Ocular redness

Brimonidine competes with phenylephrine, naphazoline and tetrahydrozoline products in OTC ocular redness. Its differentiation is based on low-dose alpha-2 agonism and positioning around temporary redness relief. Competitors may offer lower prices, broader distribution or longer consumer familiarity.

Brimonidine also competes indirectly with prescription products used for dry eye, allergy and inflammation. These products address different causes of redness and are not direct formulation substitutes.

Rosacea erythema

Mirvaso competes with oxymetazoline products such as Rhofade, which use an alpha-1 adrenergic mechanism. The commercial comparison centers on onset, duration, rebound or worsening erythema, tolerability, vehicle feel, dosing convenience and payer coverage.

A brimonidine product with superior cosmetic acceptability may compete effectively even without a new mechanism. In dermatology, adherence is strongly influenced by sensory properties and ease of application.

What generic launch scenarios exist for brimonidine?

The most likely scenarios are:

1. Standard ophthalmic generic entry continues to erode Alphagan P pricing and share.
2. Branded products retain segments where preservative systems, physician preference or device attributes affect prescribing.
3. Topical gel competition emerges after applicants resolve formulation-equivalence and patent issues.
4. New branded products use excipients and packaging to create differentiated, but narrower, market segments.
5. OTC competition focuses on price, bottle design and consumer distribution rather than active-ingredient novelty.
6. Sustained-release or combination products seek premium pricing but face longer development timelines and more complex regulatory requirements.

Revenue exposure is highest for products with chronic glaucoma use, but the price erosion risk is also highest there. The OTC and dermatology products may have greater gross-margin potential because branding and formulation experience influence purchase decisions, although consumer and payer access costs can be substantial.

What licensing opportunities exist for brimonidine excipient technology?

The most attractive licensing assets are platform technologies that apply beyond brimonidine:

• Preservative-free multidose ophthalmic containers.
• Mucoadhesive or in situ gel systems.
• Low-irritation oxidative preservation.
• Metered dermal pumps.
• Foam or cream-gel delivery systems.
• Stability-enhancing excipient combinations.
• In vitro performance methods that support topical equivalence.

A brimonidine-only formulation patent has a smaller transaction universe unless it provides a clear clinical benefit or protects a device-linked product. A platform excipient or packaging technology can support licensing across glaucoma, dry eye, allergy, rosacea and other topical products.

Geographic coverage also matters. U.S. rights may have the highest value because of the size of the branded and generic markets, while European and Asian rights can support separate launches with different regulatory and prescription dynamics. Patent term, local formulation requirements and regulatory data exclusivity should be reviewed in each jurisdiction.

Key Takeaways

• Brimonidine is a mature active ingredient with differentiated commercial value by route and dose.
• Generic risk is high for conventional ophthalmic glaucoma solutions.
• Preservative-free multidose ophthalmic delivery is the strongest near-term excipient opportunity.
• Mirvaso-style topical gels remain more defensible than simple brimonidine solutions because local equivalence is more complex.
• Brimonidine's safety profile limits aggressive penetration enhancement and high-exposure sustained-release designs.
• Device patents, formulation patents and manufacturing know-how may provide more value than active-ingredient patents.
• OTC ocular redness products depend heavily on branding, packaging and consumer tolerability.
• The most scalable licensing opportunities involve excipient and delivery platforms applicable to multiple drugs.
• Orange Book listings, Paragraph IV certifications and settlement agreements must be reviewed separately for each brimonidine product.
• Competitive diligence should distinguish Alphagan P, Lumify and Mirvaso rather than treating brimonidine as a single market.

FAQs

Can brimonidine be formulated as a preservative-free eye drop?

Yes. Preservative-free unit-dose and multidose approaches are technically feasible, but the product must maintain sterility, dose uniformity, stability and acceptable container-closure performance throughout the labeled use period.

Is a brimonidine foam likely to be commercially differentiated?

Potentially. A foam could improve spreadability, reduce residue and provide a distinct patient experience for facial erythema. It would require formulation, device, local tolerability and clinical-performance data.

Does changing the excipient system avoid brimonidine patent infringement?

Not necessarily. A different excipient may avoid a narrow composition claim, but method-of-use, concentration, process, device and packaging claims can still create infringement risk.

What is the most valuable brimonidine product-development niche?

A preservative-free multidose ophthalmic product with demonstrable ocular-surface tolerability and a reliable low-waste container is the most commercially practical niche. A long-acting product has greater potential differentiation but materially higher regulatory and safety risk.

Can brimonidine be combined with another rosacea treatment?

Yes, but the combination would require regulatory support for the combined product and must show that the components provide a clinically meaningful benefit without increasing irritation, rebound erythema or systemic exposure.

References

1. U.S. Food and Drug Administration. (2013). Alphagan P (brimonidine tartrate ophthalmic solution) prescribing information.
2. U.S. Food and Drug Administration. (2017). Mirvaso (brimonidine tartrate) gel prescribing information.
3. U.S. Food and Drug Administration. (2018). Lumify (brimonidine tartrate ophthalmic solution) prescribing information.
4. U.S. Food and Drug Administration. (2022). Draft guidance for industry: Ophthalmic drug products submitted under an ANDA.
5. U.S. Food and Drug Administration. (2025a). Approved drug products with therapeutic equivalence evaluations, Orange Book.
6. U.S. Food and Drug Administration. (2025b). Product-specific guidances for generic drug development.